

IAP7 Rec'd PCT/PTO 10 JAN 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert S. Meissner et al

Serial No. 10/551,975

Filed: October 5, 2005

For: ANDROGEN RECEPTOR MODULATORS AND
METHODS OF USE THEREOFArt Unit: To Be AssignedExaminer: To Be AssignedCommissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Pamela Spalding Date 1-5-06

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

| RELATED APPLICATION | | |
|---------------------|-------------|------------|
| U. S. SERIAL NUMBER | FILING DATE | MERCK CASE |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Patricia A. Shatynski

By: Patricia A. Shatynski

Attorney _____ For Applicant(s)

Reg. No. 43,109

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-1652

Date: January 5, 2006

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

| | |
|-----------------------------|--------------------|
| Application Number | 10/551,975 |
| Filing Date | October 5, 2005 |
| First Named Inventor | Robert S. Meissner |
| Group Art Unit | To Be Assigned |
| Examiner Name | To Be Assigned |
| Attorney Docket Number | 20880P |

Sheet

1

of

2

Attorney Docket Number 20880P

[illegible][illegible]Examiner
SignatureDate
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

COMPLETE IF KNOWN**Application Number**

10/551,975

Filing Date

October 5, 2005

First Named Inventor

Robert S. Meissner

Group Art Unit

To Be Assigned

Examiner Name

To Be Assigned

Attorney Docket Number

20880P

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

1

M. Lourdasamy et al., "Synthesis and In Vitro Study of 17 beta-[N-Ureylene-N,N'-disubstituted]-4-methyl-4-aza-5 alpha-Androstan-3-ones as Selective Inhibitors of Type I 5 alpha-Reductase". Bioorganic & Medicinal Chemistry, Vol. 5, pp 305-310, 1997

2

X. Li et al., "Synthesis and in Vitro Activity of 17 beta-(N-Alkyl/arylformamido)- and 17 beta-[(N-Alkyl/aryl)alkyl/arylamido]-4-methyl-4-aza-3-oxo-5 alpha-androstan-3-.....", J. Med. Chem, Vol. 38, pp 1158-1173, 1995

3

C. Chen et al., "Activity of 17 beta-(N-Alkyl/arylformamido) and 17 beta-[N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5a-androstan-3-ones as 5 alpha-Reductase Inhibitors in the Hamster Flank Organ and Ear", The Journal of Investigative Dermatology, Vol. 111, pp 273-278, 1998

4

G.H. Rasmusson et al., "Azasteroids: Structure-Activity Relationships for Inhibition of 5 alpha-Reductase and of Androgen Receptor Binding", J. Med. Chem., Vol. 29, pp 2298-2315, 1986

5

G.H. Rasmusson et al., "Azasteroids as Inhibitors of Rat Prostatic 5 alpha-Reductase", J. Med. Chem , Vol. 27, pp 1690-1701, 1984

6

W.E. Solomons et al., "Synthesis and Antimicrobial Properties of 17 beta-Amino-4-aza-5 alpha-androstane and Derivatives", *Journal of Pharmaceutical Sciences*, Vol 63, pp 19-23, 1974

Examiner
SignatureDate
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005